The EPS miss and worsening stockholders' deficit signal ongoing cash burn and potential financing needs. Monitor the upcoming conference call for updates on cash runway and partnership finalization; the stock's low market cap ($4M) amplifies sensitivity to any liquidity news.
Price Chart
Executive Summary
Vivos Therapeutics reported Q2 2026 revenue of $5.2M, up 35% YoY, but EPS of -$0.31 missed consensus of -$0.39 by 20.5%. Revenue growth was driven by service revenue from Nevada operations, but operating losses remained flat at $4.8M and cash burn continues with $1.8M in cash and a stockholders' deficit of $3.8M. The company highlighted increased patient referrals and AI-enabled software conversion as catalysts, but the EPS miss and negative equity position are concerning for a micro-cap with limited liquidity.
Key Financial Metrics
Key Facts
- Revenue of $5.2M for Q2 2026, up 35% YoY from $3.8M
- EPS of -$0.31 vs consensus -$0.39, a 20.5% miss
- Gross margin improved to 57% from 55% YoY
- Operating loss of $4.8M, flat YoY
- Cash and equivalents of $1.8M at June 30, 2026, down from $2.0M at Dec 31, 2025
- Stockholders' deficit of $3.8M, worsening from $1.5M deficit at Dec 31, 2025
- Weighted average shares outstanding increased to 17.7M from 9.1M YoY, reflecting dilution
Financial Impact
EPS miss of 20.5% on consensus -$0.39, revenue beat of $5.2M vs $5.8M consensus (10.3% miss)
Risk Factors
- Cash burn continues with only $1.8M in cash and a $3.8M stockholders' deficit
- Dilution risk from increased share count (17.7M vs 9.1M YoY)
- Nasdaq listing risk due to negative stockholders' equity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345627 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $0.1347 | awaiting T+60 | — | $0.1230 (−8.69%) |
Oct 19, 2026 7d ago | Press Release | $0.1410 | awaiting T+60 | — | $0.1230 (−12.77%) |
Oct 19, 2026 7d ago | 8-K | $0.1406 | awaiting T+60 | — | $0.1230 (−12.52%) |
Oct 15, 2026 12d ago | 8-K | $0.1428 | awaiting T+60 | — | $0.1230 (−13.87%) |
Oct 15, 2026 12d ago | Press Release | $0.1428 | awaiting T+60 | — | $0.1230 (−13.87%) |
Sep 30, 2026 26d ago | 8-K | $0.1490 | awaiting T+60 | — | $0.1230 (+17.45%) |
Aug 28, 2026 8w ago | Press Release | $0.2249 | awaiting T+60 | — | $0.1230 (−45.31%) |
Aug 21, 2026 9w ago | 8-K | $0.2768 | awaiting T+60 | — | $0.1230 (−55.56%) |
Aug 14, 2026 10w ago | Press Release | $0.3012 | awaiting T+60 | — | $0.1230 (+59.16%) |
Aug 14, 2026 10w ago | Press Release | $0.3433 | awaiting T+60 | — | $0.1230 (−64.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers